Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/35423
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shelton E. | en |
dc.contributor.author | Ward M.G. | en |
dc.contributor.author | Roblin X. | en |
dc.contributor.author | Little R.D. | en |
dc.contributor.author | Chu I.E. | en |
dc.contributor.author | Connor S.J. | en |
dc.contributor.author | Van Der Zanden E.P. | en |
dc.contributor.author | Flanagan E. | en |
dc.contributor.author | Bell S.J. | en |
dc.contributor.author | Gibson P.R. | en |
dc.contributor.author | Sparrow M.P. | en |
dc.date.accessioned | 2021-05-14T11:58:07Z | en |
dc.date.available | 2021-05-14T11:58:07Z | en |
dc.date.copyright | 2019 | en |
dc.date.created | 20200211 | en |
dc.date.issued | 2020-02-11 | en |
dc.identifier.citation | Journal of Crohn's and Colitis. 13 (12) (pp 1527-1536), 2019. Date of Publication: 10 Dec 2019. | en |
dc.identifier.issn | 1873-9946 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/35423 | en |
dc.description.abstract | Background: Adalimumab is administered via a pre-filled syringe or spring-loaded pen. In a previous study in Crohn's disease, higher drug levels were observed in syringe users. The aim of this study was to evaluate the impact of delivery device on adalimumab drug levels in patients with Crohn's disease. Method(s): Consecutive Crohn's disease patients treated with maintenance adalimumab [40 mg fortnightly] were recruited from five centres. The first recorded drug level with matched clinical and biochemical markers of disease activity was compared between pen and syringe users. Result(s): Of 218 patients, 64% used pen, with a median faecal calprotectin 110 mug/g and serum C-reactive protein 4 mg/L. In comparison to pen, syringe users had higher albumin [39 vs 42 g/L; p = 0.016], lower Harvey-Bradshaw Index [2 vs 1; p = 0.017], and higher rates of concomitant immunomodulation [54% vs 71%; p = 0.014]. Drug levels were equivalent between pen and syringe users [median 5.3 vs 5.2 mug/ml; p = 0.584], even after controlling for disease activity and immunomodulation. Syringe users at Alfred Health had higher drug levels than pen [6.1 vs 4.5 mug/ml; p = 0.039]; a greater proportion achieved therapeutic levels [75% vs 44%; p = 0.045]. A higher proportion of pen users from Saint-Etienne had therapeutic levels [79% vs 42%; p = 0.027], yet no significant difference in drug levels [7.9 vs 4.5 mug/ml; p = 0.119]. Conclusion(s): Delivery device does not appear to significantly affect adalimumab drug levels. Given differences between study sites, studies evaluating administration education and technique are warranted.Copyright © 2019 European Crohn's and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. | en |
dc.language | English | en |
dc.language | en | en |
dc.publisher | Oxford University Press | en |
dc.relation.ispartof | Journal of Crohn's and Colitis | en |
dc.subject.mesh | drug blood level | - |
dc.subject.mesh | biochemistry | - |
dc.subject.mesh | Crohn disease | - |
dc.subject.mesh | disease activity | - |
dc.subject.mesh | disease control | - |
dc.subject.mesh | immunomodulation | - |
dc.subject.mesh | maintenance therapy | - |
dc.subject.mesh | protein blood level | - |
dc.subject.mesh | adalimumab | - |
dc.subject.mesh | C reactive protein | - |
dc.subject.mesh | calgranulin | - |
dc.subject.mesh | drug delivery device/dc [Device Comparison] | - |
dc.subject.mesh | syringe/dc [Device Comparison] | - |
dc.subject.mesh | Pen/dc [Device Comparison] | - |
dc.title | Comparison of Adalimumab Serum Drug Levels When Delivered by Pen Versus Syringe in Patients with Inflammatory Bowel Disease. An International, Multicentre Cohort Analysis. | en |
dc.type | Article | en |
dc.identifier.affiliation | Gastroenterology and Hepatology | - |
dc.type.studyortrial | Observational study (cohort, case-control, cross sectional or survey) | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1093/ecco-jcc/jjz103 | - |
dc.publisher.place | United Kingdom | en |
dc.identifier.pubmedid | 31094417 [http://www.ncbi.nlm.nih.gov/pubmed/?term=31094417] | en |
dc.identifier.source | 630810127 | en |
dc.identifier.institution | (Little, Chu, Gibson, Sparrow, Ward) Department of Gastroenterology, Alfred Health and Monash University, Melbourne, VIC, Australia (Van Der Zanden, Connor) Department of Gastroenterology, Liverpool Hospital, University of New South Wales, Sydney, NSW, Australia (Flanagan, Bell) Department of Gastroenterology, St Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia (Shelton) Department of Gastroenterology, Monash Health and Monash University, Melbourne, VIC, Australia (Roblin) Gastro-enterologie et Hepatologie, CHU Saint-Etienne, Saint-Etienne, France | en |
dc.description.address | M.G. Ward, Department of Gastroenterology, Alfred Health and Monash University, Melbourne, VIC 3004, Australia. E-mail: m.ward@alfred.org.au | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2020 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | adalimumab Crohn's disease therapeutic drug monitoring | en |
dc.identifier.authoremail | Ward M.G.; m.ward@alfred.org.au | en |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.openairetype | Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
crisitem.author.dept | Gastroenterology and Hepatology | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.